JBIO
Jade Biosciences, Inc.
Key Financials
Operating Income
$-113542000
↓ 52.2%
Net Income
$-127410000
↓ 83.0%
EPS (Diluted)
$-3.19
↓ 30.7%
Shareholders' Equity
$332.5M
↑ 335.0%
Total Liabilities
$17.3M
↑ 342.9%
Total Assets
$349.8M
↑ 335.4%
Cash & Equivalents
$88.4M
↑ 162.0%
Operating Cash Flow
$-94689000.00
↓ 33.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/10/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
| SCHEDULE 13G | 7/17/2026 | View on SEC |
| SCHEDULE 13G/A | 7/8/2026 | View on SEC |
| 8-K | 7/1/2026 | View on SEC |
| 4 | 6/26/2026 | View on SEC |
| 3 | 6/26/2026 | View on SEC |
| 8-K | 6/26/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | JBIO |
| Company Name | Jade Biosciences, Inc. |
| CIK | 1798749 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (781) 312-3013 |